Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 151 AL 165

Cholinesterase inhibitors as Alzheimer's therapeutics (Review)

Sharma K.

Mol Med Rep. 2019 Aug;20(2):1479-1487. doi: 10.3892/mmr.2019.10374. Epub 2019 Jun 11.

Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis

Glinz D, Gloy VL, Monsch AU, Kressig RW, Patel C, McCord KA, Ademi Z, Tomonaga Y, Schwenkglenks M, Bucher HC, Raatz H.

Swiss Med Wkly. 2019 Jun 30;149:w20093. doi: 10.4414/smw.2019.20093. eCollection 2019 Jun 17.

Current and emerging avenues for Alzheimer's disease drug targets

Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, Zusso M, Robert P, Frisoni GB, Cattaneo A, Zille M, Boltze J, Cartier N, Buee L, Johansson G, Winblad B.

J Intern Med. 2019 Oct;286(4):398-437. doi: 10.1111/joim.12959. Epub 2019 Aug 29.

Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease

Vijayan DK, Zhang KYJ.

Pharmacol Res. 2019 Sep;147:104342. doi: 10.1016/j.phrs.2019.104342. Epub 2019 Jul 6.

Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease

Veening-Griffioen DH, Ferreira GS, van Meer PJK, Boon WPC, Gispen-de Wied CC, Moors EHM, Schellekens H.

Eur J Pharmacol. 2019 Sep 15;859:172524. doi: 10.1016/j.ejphar.2019.172524. Epub 2019 Jul 7.

Cu(II) Binding Properties of N-Truncated Aβ Peptides: In Search of Biological Function

Stefaniak E, Bal W.

Inorg Chem. 2019 Oct 21;58(20):13561-13577. doi: 10.1021/acs.inorgchem.9b01399. Epub 2019 Jul 15.

Advancements in nanotherapeutics for Alzheimer's disease: current perspectives

Harilal S, Jose J, Parambi DGT, Kumar R, Mathew GE, Uddin MS, Kim H, Mathew B.

J Pharm Pharmacol. 2019 Sep;71(9):1370-1383. doi: 10.1111/jphp.13132. Epub 2019 Jul 15.

Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review

Silva GM, Barcelos MP, Poiani JGC, Hage-Melim LIDS, da Silva CHTP.

ChemMedChem. 2019 Aug 20;14(16):1467-1483. doi: 10.1002/cmdc.201900299. Epub 2019 Aug 1.

Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential

Angelopoulou E, Piperi C.

Neuromolecular Med. 2019 Sep;21(3):227-238. doi: 10.1007/s12017-019-08558-2. Epub 2019 Jul 16.

Diabetes drugs in the fight against Alzheimer's disease

Boccardi V, Murasecco I, Mecocci P.

Ageing Res Rev. 2019 Sep;54:100936. doi: 10.1016/j.arr.2019.100936. Epub 2019 Jul 19.

Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications

Chantran Y, Capron J, Alamowitch S, Aucouturier P.

Front Immunol. 2019 Jul 4;10:1534. doi: 10.3389/fimmu.2019.01534. eCollection 2019.

Targeting apolipoprotein E for treating Alzheimer's disease

Bales KR, Paul SM.

Neurosci Lett. 2019 Sep 14;709:134366. doi: 10.1016/j.neulet.2019.134366. Epub 2019 Jul 20.

The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease

Kim B, Elzinga SE, Henn RE, McGinley LM, Feldman EL.

Neurobiol Dis. 2019 Dec;132:104541. doi: 10.1016/j.nbd.2019.104541. Epub 2019 Jul 23.

Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships

Xu M, Peng Y, Zhu L, Wang S, Ji J, Rakesh KP.

Eur J Med Chem. 2019 Oct 15;180:656-672. doi: 10.1016/j.ejmech.2019.07.059. Epub 2019 Jul 22.

Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders

Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G.

Neurotherapeutics. 2019 Jul;16(3):666-674. doi: 10.1007/s13311-019-00767-8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias